Benign Familial Recurrent Cholestasis (BRIC)

Benign familial recurrent cholestasis (BRIC) is a rare, inherited liver condition. “Benign” means it does not usually lead to permanent liver damage. “Familial” means it runs in families. “Recurrent” means the problem comes and goes in episodes. “Cholestasis” means bile cannot flow well from the liver to the intestine. During attacks, bile builds up in the liver and blood. This causes intense itching, yellow eyes and skin (jaundice), dark urine, pale stools, poor appetite, and tiredness. Each attack can last weeks to months. Then it goes away on its own, and the person feels normal again between attacks. In most people, liver tests return to near normal between episodes, and long-term scarring (cirrhosis) is uncommon. BRIC is part of a spectrum with another group of diseases called PFIC (progressive familial intrahepatic cholestasis). PFIC is the severe, long-lasting end of the spectrum; BRIC is the milder, on-and-off end.

Benign familial recurrent cholestasis is a rare, inherited liver condition. People with this condition have attacks (or episodes) where their liver cannot move bile out of the liver cells the way it should. During an attack, bile chemicals build up in the blood. This causes severe itching, yellow eyes and skin (jaundice), dark urine, and pale stools. The attacks last weeks to months, then go away on their own. Between attacks, most people feel normal and the liver usually looks normal. Because the problem sits inside the liver (not in the bile ducts outside), doctors call it intrahepatic cholestasis. “Benign” here means it does not usually lead to permanent liver failure, but some people can still have many difficult attacks and need treatment for symptoms. Genomics Education Programme+3MedlinePlus+3PMC+3

BRIC is a rare, inherited liver condition that causes repeated attacks (episodes) of cholestasis—when bile cannot flow out of the liver properly. During attacks, people develop intense itch, jaundice (yellow skin/eyes), dark urine, pale stools, fatigue, and poor appetite. Between attacks, liver tests can go back to normal and people feel well. Two main types exist: BRIC1 (usually from changes in the ATP8B1 gene) and BRIC2 (usually from changes in ABCB11, which encodes the bile salt export pump, BSEP). The disorder is typically autosomal recessive. MedlinePlus+3Orpha+3PMC+3

Why it happens

 The genes involved control proteins that keep bile salts moving properly. When they don’t work well, bile acids accumulate, leading to itch and jaundice during attacks. Some guidelines group BRIC within the spectrum of genetic cholestatic diseases. PMC+2Journal of Hepatology+2

BRIC happens because of changes (variants) in certain genes that help move bile out of liver cells. The two main genes are ATP8B1 (also called FIC1) and ABCB11 (also called BSEP). When these transport systems run slowly or get overwhelmed, bile acids “back up.” This backup triggers itching and jaundice without a blockage in the bile ducts. Many people with BRIC notice attacks after a trigger such as an infection, certain medicines, or hormonal changes. Treatment is aimed at relieving itching, supporting nutrition, avoiding triggers, and, in tough episodes, draining bile through special procedures. Most people live a normal life span.

Other names

Doctors and genetics sites may use several names for the same condition:

• Benign recurrent intrahepatic cholestasis (BRIC)

• Recurrent familial intrahepatic cholestasis

• Summerskill syndrome (an older term you might see in papers)
  These are all talking about the same clinical picture of repeat cholestasis attacks that get better between episodes. UniProt

Types

There are two main genetic types:

• BRIC type 1 (BRIC1) – linked to changes in the ATP8B1 gene (also called FIC1). People with this type have repeat cholestasis with low or normal GGT blood tests. MDPI+1

• BRIC type 2 (BRIC2) – linked to changes in the ABCB11 gene, which makes the Bile Salt Export Pump (BSEP). This type also shows low/normal GGT and similar attacks. ScienceDirect+1

BRIC sits on a spectrum with Progressive Familial Intrahepatic Cholestasis (PFIC). BRIC behaves in bouts and usually does not cause ongoing scarring, while PFIC tends to be continuous and can progress to liver damage. Many experts see BRIC as the episodic end of some PFIC gene problems. PFIC+1

The liver makes bile to help digest fat and carry waste products out of the body. In BRIC, tiny “transporters” in the liver cell membrane do not handle bile acids normally. During an attack, bile acids and other bile ingredients back up in the body. This causes itching (bile acids and related molecules irritate skin nerves), jaundice (bilirubin builds up), and pale stools (less bile reaches the gut). Between attacks, the transporters work well enough that the liver tests can return to normal. The genes ATP8B1 and ABCB11 are the usual roots of the problem. ScienceDirect+1

---

Causes

The root cause is inherited gene changes in ATP8B1 (BRIC1) or ABCB11/BSEP (BRIC2). On top of that, many people notice triggers that seem to set off an attack. Not everyone has the same triggers, but these are commonly reported or biologically plausible:

1. Genetic cause (ATP8B1 variants) – changes in this gene disturb normal bile handling inside liver cells, setting the stage for attacks. ScienceDirect

2. Genetic cause (ABCB11/BSEP variants) – reduced export of bile acids out of the liver; during stressors, bile acids back up more and provoke symptoms. ScienceDirect

3. Intercurrent viral infections (e.g., flu, COVID-19) – illnesses can tip bile transporters into dysfunction and precipitate an episode. Case reports describe flares after these infections. AGEB+1

4. Bacterial infections – general systemic inflammation can trigger cholestasis in genetically susceptible people. AGEB

5. Fever or significant physical stress – stress hormones and inflammatory signals can disturb bile flow. AGEB

6. Certain medications – especially drugs that affect bile transport (estrogens, some antibiotics, and other cholestatic drugs) can uncover BSEP-related vulnerability. AGEB

7. Hormonal changes (e.g., pregnancy) – pregnancy hormones can worsen bile acid flow in susceptible people, similar to intrahepatic cholestasis of pregnancy biology. Genomics Education Programme

8. Estrogen-containing oral contraceptives – estrogens can reduce bile flow and provoke symptoms in those with BSEP/FIC1 problems. Genomics Education Programme

9. Dehydration – lowers hepatic perfusion and can aggravate cholestasis during a vulnerable period. (Inference consistent with cholestatic triggers; clinicians often advise good hydration.)

10. Poor sleep or overexertion – stressors that may nudge a borderline bile-flow state into a flare. (Clinical inference.)

11. Fast weight loss or fasting – rapid changes in bile composition and gallbladder emptying can stress bile flow. (Clinical inference; consistent with cholestasis mechanisms.)

12. Very high-fat meals – temporarily increase bile demand; in a borderline state this may push toward symptoms. (Mechanistic inference.)

13. Alcohol binges – alcohol can impair hepatocyte function and transiently worsen cholestasis in susceptible people. (General hepatology principle.)

14. Surgery or anesthesia – physiologic stress, drugs, and fasting around procedures can precipitate an episode. (Clinical inference.)

15. Travel-related stress or infections – combined stressors that may trigger attacks. (Clinical inference.)

16. Environmental toxins/solvents – rare but possible triggers that strain bile secretion pathways. (General toxicology principle.)

17. Coexisting liver hits (e.g., hepatitis A/E) – additional hepatic stressors can reveal cholestatic tendency. (General hepatology principle.)

18. Metabolic stress (poorly controlled diabetes or thyroid shifts) – endocrine changes can alter bile formation and flow. (Mechanistic inference.)

19. New herbal supplements – some can be cholestatic; always share supplement lists with clinicians. (General DILI principle.)

20. Unknown/idiopathic triggers – many attacks have no clear trigger despite good detective work; this is common in BRIC. PMC

Notes on evidence: The genes and infection/hormone/drug triggers are well described in reviews and case series; several items above are reasoned extensions of cholestasis biology used in everyday hepatology counseling. Genomics Education Programme+3ScienceDirect+3MDPI+3

---

Symptoms

1. Itching (pruritus) – often the most distressing symptom; it can be severe, worse at night, and disturb sleep. PMC

2. Yellow eyes/skin (jaundice) – bilirubin builds up when bile cannot flow normally. MedlinePlus

3. Dark urine – excess conjugated bilirubin is excreted in urine. MedlinePlus

4. Pale or clay-colored stools – less bile pigment reaches the intestines. MedlinePlus

5. Fatigue and low energy – common during attacks because the body is dealing with toxin buildup and poor fat digestion. Genomics Education Programme

6. Poor appetite and early fullness – nausea and bile-related dyspepsia can reduce intake. Genomics Education Programme

7. Nausea or vomiting – especially during stronger flares. Genomics Education Programme

8. Abdominal discomfort or right-upper-quadrant heaviness – the liver capsule can feel tight when bile backs up. (Clinical description consistent with cholestasis.)

9. Sleep disturbance – itching is worse at night and breaks sleep. PMC

10. Mood changes, irritability, or low mood – chronic itch and insomnia affect mental health. (Common pruritus impact.)

11. Weight loss during long attacks – due to poor appetite and malabsorption of fat. (Mechanistic explanation of cholestasis.)

12. Dry skin and scratch marks – from constant itching. (Clinical observation.)

13. Easy bruising – if vitamin K absorption falls during prolonged cholestasis, clotting can be impaired. (Fat-soluble vitamin biology.)

14. Bone or muscle aches – low vitamin D during long flares may cause aches. (Fat-soluble vitamin biology.)

15. Vision issues in very prolonged disease – rare; long-term vitamin A deficiency can affect night vision. (Fat-soluble vitamin biology.)

---

Diagnostic tests

What doctors aim to do:
(1) Prove that cholestasis is happening inside the liver; (2) rule out a blockage in the bile ducts; (3) look for the genetic cause; and (4) check for complications (like vitamin shortages). Classic BRIC diagnostic criteria include: at least two attacks, symptom-free gaps, lab evidence of intrahepatic cholestasis, normal bile ducts on imaging, biopsy showing cholestasis during an attack, and no other cause (like stones or hepatitis). MDPI+1

A) Physical examination

1. Skin and eye exam for jaundice – doctors look for yellowing and scratching marks; this supports a cholestatic picture when labs agree. MedlinePlus

2. General scratch-mark check – widespread linear scratches and thickened skin from chronic itch point toward long-standing pruritus. (Clinical sign.)

3. Liver size by gentle palpation/percussion – the liver is often normal or only mildly enlarged in BRIC between attacks; big, hard livers suggest other diseases. (Clinical sign; part of ruling out other causes.)

4. Stool and urine color review – dark urine and pale stools are classic cholestasis clues that can be confirmed with simple observation. MedlinePlus

5. Nutrition and vitamin status check – looking for easy bruising, bone tenderness, or night-vision problems if attacks are prolonged (vitamins K, D, A). (Standard cholestasis practice.)

B) “Manual bedside tests and simple office tools

6. Urine dipstick for bilirubin – a simple strip can detect conjugated bilirubin in urine during attacks and supports a cholestatic pattern. (Common bedside test.)

7. Icterometer / scleral color comparison – a simple clinical gauge to grade jaundice visually, used along with blood tests. (Bedside aid.)

8. Abdominal percussion for liver span – a quick manual estimate; marked enlargement pushes clinicians to look for different liver diseases. (Bedside exam.)

9. Pruritus severity scale (e.g., Visual Analog Scale or 5-D Itch) – a paper-and-pencil scale to quantify itch over time and treatment response. (Widely used symptom scales.)

10. Bedside stool color card – comparing stool color to a card can support the cholestasis impression in children and adults. (Simple clinical tool.)

C) Laboratory and pathological tests

11. Serum bilirubin (total and direct) – high direct (conjugated) bilirubin fits cholestasis and explains dark urine and jaundice. MedlinePlus

12. Alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) – ALP usually rises during attacks; GGT is often normal or low in BRIC1/BRIC2, which helps point away from other cholestatic diseases. PMC

13. Alanine and aspartate aminotransferases (ALT/AST) – may be normal or mildly raised; big spikes suggest other problems. (General hepatology.)

14. Serum bile acids – typically elevated during an attack and support the diagnosis. Genomics Education Programme

15. Coagulation tests (PT/INR) and vitamin K trial – prolonged PT that corrects after vitamin K points to fat-soluble vitamin malabsorption during cholestasis. (Standard practice in cholestasis.)

16. Fat-soluble vitamin levels (A, D, E, K) – to detect deficiencies if attacks are long or frequent. (Standard practice.)

17. Genetic testing for ATP8B1 and ABCB11 – confirms BRIC1 or BRIC2 and helps counsel families; many reports document disease-causing variants. Turkish Archives of Pediatrics+1

18. Liver biopsy during an attack – shows centrilobular/canalicular cholestasis with little inflammation or scarring; this is part of classic criteria when imaging is normal. MDPI

D) Electrodiagnostic tests

(Used selectively to evaluate complications of prolonged cholestasis, mainly fat-soluble vitamin deficiencies, not to “prove” BRIC itself.)

19. Nerve conduction studies (NCS) – long attacks can lower vitamin E, which can lead to peripheral neuropathy; NCS helps if numbness or weakness appears. (Complication assessment.)

20. Electromyography (EMG) – supports NCS when weakness suggests neuromuscular involvement from vitamin deficiencies. (Complication assessment.)

21. Electroretinogram (ERG) – rarely used, but can check retinal function if severe, prolonged vitamin A deficiency is suspected (for night-vision complaints). (Complication assessment.)

E) Imaging tests

22. Right-upper-quadrant ultrasound – first-line imaging to rule out extrahepatic blockage (stones, masses). In BRIC, bile ducts look normal. MDPI

23. MRCP (magnetic resonance cholangiopancreatography) – noninvasive pictures of the biliary tree to exclude strictures or stones when ultrasound is unclear; ducts are typically normal in BRIC. MDPI

24. ERCP (endoscopic study) – rarely needed just to diagnose BRIC; reserved for special cases or when therapy (like temporary drainage) is considered. (Diagnostic-therapeutic role.)

25. Transient elastography (FibroScan) – checks liver stiffness (scarring). BRIC usually shows little to no fibrosis between attacks, which helps separate it from progressive diseases. (Assessment tool on the BRIC–PFIC spectrum.) PFIC

Non-pharmacological treatments (therapies & other measures)

1. Cool skin care + emollients during itch
   Description: Take lukewarm (not hot) showers, pat skin dry, apply fragrance-free moisturizers and optional menthol gels. Purpose: Reduce itch triggers and protect the skin barrier. Mechanism: Cooling and moisturizers reduce nerve activation and water loss from the skin, lowering itch sensation and scratching injury. AASLD

2. Loose, breathable clothing & short nails
   Description: Wear soft, loose cotton; keep nails trimmed; use cotton gloves at night if scratching. Purpose: Minimize skin irritation and skin breaks. Mechanism: Less friction and shorter nails reduce skin trauma and the itch-scratch cycle. AASLD

3. Sleep hygiene & stress reduction
   Description: Keep a regular sleep time, dark cool room, and brief relaxation before bed. Purpose: Lower night-time itch perception and fatigue. Mechanism: Better sleep modulates central itch processing and daytime resilience. AASLD

4. Mind–body techniques (CBT/relaxation)
   Description: Brief, structured coping strategies for itch and stress; breathing exercises and guided imagery. Purpose: Reduce distress and scratching urges. Mechanism: Alters brain attention to itch and reduces sympathetic arousal. (Direct BRIC trials are limited, but guidance for cholestatic itch supports behavioral measures.) AASLD

5. Avoid heat and hot water
   Description: Keep rooms cool, avoid saunas/hot baths. Purpose: Prevent itch flares. Mechanism: Heat increases skin blood flow and nerve firing that amplifies itch. AASLD

6. Trigger review during attacks
   Description: With a clinician, check for new drugs, infections, fasting, dehydration. Purpose: Find reversible causes that can worsen cholestasis. Mechanism: Removing a trigger may shorten an attack. (General cholestasis guidance.) PMC

7. Optimized nutrition with adequate calories/protein
   Description: Small, frequent meals; dietitian input in prolonged attacks. Purpose: Prevent weight loss and muscle loss. Mechanism: Illness/anorexia increase needs; balanced intake maintains strength. ESPN Clinical Nutrition

8. Fat-soluble vitamin monitoring (A, D, E, K)
   Description: Check levels when bilirubin stays >2 mg/dL or during long attacks; replace if low. Purpose: Prevent bone, vision, nerve, and bleeding problems. Mechanism: Cholestasis reduces bile in gut, lowering vitamin absorption. PMC+1

9. Calcium + bone health practices
   Description: Weight-bearing activity, vitamin D sufficiency, bone density checks if prolonged cholestasis. Purpose: Reduce bone loss risk. Mechanism: Vitamin D malabsorption and inflammation harm bones. AASLD

10. Medium-chain triglycerides (MCT) as needed
    Description: If fat malabsorption/weight loss appears, use MCT oil or MCT-rich formulas short-term with clinician/dietitian guidance. Purpose: Improve energy intake when fat absorption is poor. Mechanism: MCTs absorb without micelles/bile; caution: they supply fewer calories than long-chain fats and can reduce essential fatty acids if overused. UVA School of Medicine+1

11. Hydration & regular bowel habits
    Description: Fluids and fiber within tolerance. Purpose: Support bile acid binding therapies and comfort. Mechanism: Prevents constipation that can worsen pruritus perception. PMC

12. Avoid alcohol during attacks
    Description: Abstain until labs normalize. Purpose: Reduce additional liver stress. Mechanism: Alcohol metabolism increases hepatic burden during cholestasis. ESPN Clinical Nutrition

13. Photo-protective habits during jaundice
    Description: Sunscreen, hats. Purpose: Protect itchy, fragile skin. Mechanism: Minimizes UV-induced irritation. PMC

14. Itch diaries
    Description: Track daily itch (0–10), sleep, stools, urine color, and triggers. Purpose: Evaluate response to treatments and timing of attacks. Mechanism: Structured monitoring guides step-wise therapy. AASLD

15. Early evaluation for obstructive causes each attack
    Description: Clinician checks labs and ultrasound if atypical pain/fever. Purpose: Rule out gallstones or strictures. Mechanism: Fixing a mechanical block helps symptoms. PMC

16. Vaccinations up to date
    Description: Hepatitis A/B as indicated; routine vaccines. Purpose: Protect liver from added injury. Mechanism: Preventable infections can worsen cholestasis outcomes. PMC

17. Gentle exercise as tolerated
    Description: Short walks or stretching when energy allows. Purpose: Preserve mood and fitness. Mechanism: Supports sleep and reduces fatigue. PMC

18. Pruritus safety plan
    Description: Cover nails at night, treat skin breaks promptly. Purpose: Prevent infections from scratching. Mechanism: Reduces bacteria entry through excoriations. AASLD

19. Specialist follow-up between attacks
    Description: Hepatology/genetics visit for education and contingency plans. Purpose: Plan step-up itch treatments early in flares. Mechanism: Reduces delays and suffering. Journal of Hepatology

20. Consideration of endoscopic nasobiliary drainage (ENBD) during severe, refractory flares
    Description: A thin tube temporarily drains bile externally. Purpose: Rapidly relieves itch and lowers bile acids. Mechanism: Bile diversion decreases circulating bile salts; case series show long-lasting remission in some BRIC patients. Wiley Online Library+2PMC+2

---

Drug treatments

Stepwise approach (per guidelines): 1) Bile acid sequestrant → 2) Rifampin → 3) Opioid antagonist (naltrexone) → 4) Sertraline; consider IBAT inhibitors in related genetic cholestasis; tailor to the individual. Always check interactions and liver tests. AASLD+1

1. Cholestyramine (QUESTRAN) — Class: bile acid sequestrant. Dose/Time: 4 g 1–2×/day, titrate up to 24 g/day; take other meds ≥1–4 h apart. Purpose: First-line for cholestatic itch. Mechanism: Binds bile acids in gut so fewer return to blood; reduces pruritus. Side effects: Bloating, constipation; can reduce absorption of fat-soluble drugs/vitamins. DailyMed

2. Colesevelam — Class: bile acid sequestrant. Dose: Commonly 3.75 g/day (adult); spacing from other meds needed. Purpose/Mechanism: Similar to cholestyramine; sometimes better tolerated. Side effects: GI upset, drug interactions. (Label evidence general; used off-label for cholestatic itch.) MDPI

3. Rifampin (RIFADIN) — Class: enzyme inducer antibiotic. Dose: 150–300 mg twice daily (do not exceed 600 mg/day without specialist). Purpose: Second-line itch relief. Mechanism: Induces hepatic enzymes and transporters; reduces pruritogens (e.g., autotaxin/lysophosphatidic acid axis, bile acids). Side effects: Hepatotoxicity risk, drug interactions, orange secretions. Monitor LFTs. FDA Access Data

4. Naltrexone (REVIA/VIVITROL) — Class: opioid antagonist. Dose: Start 12.5–25 mg daily, increase to 50 mg daily if tolerated; short-acting first to test. Purpose: Third-line itch control. Mechanism: Blocks central opioid-mediated itch pathways. Side effects: Precipitates withdrawal in opioid users; nausea, headache; rare liver enzyme rise. FDA Access Data+1

5. Sertraline (ZOLOFT) — Class: SSRI antidepressant. Dose: 25–50 mg daily; titrate as needed. Purpose: Fourth-line itch option and helps mood/sleep. Mechanism: Modulates central itch perception via serotonergic pathways. Side effects: GI upset, insomnia, sexual dysfunction; interaction checks required. FDA Access Data+1

6. Ursodeoxycholic acid (UDCA; ursodiol) — Class: hydrophilic bile acid. Dose: 13–15 mg/kg/day in divided doses. Purpose: Improves bile flow in some cholestatic disorders; may ease pruritus in some patients. Mechanism: Replaces toxic bile acids; cytoprotective and choleretic. Side effects: GI upset; monitor response. FDA Access Data+1

7. Fenofibrate — Class: PPAR-α agonist (fibrate). Dose: Per label for dyslipidemia. Purpose: Adjunct for cholestatic pruritus in some conditions; improves biochemistry in cholestatic diseases (data stronger in PBC). Mechanism: Alters bile acid metabolism and pruritogens. Side effects: Liver tests, CK monitoring. (Off-label for itch.) MDPI

8. Obeticholic acid — Class: FXR agonist. Dose: As per label (for PBC). Purpose: Not a standard BRIC therapy; occasionally considered experimentally for cholestasis but can worsen pruritus; specialist use only. Mechanism: FXR activation modulates bile acid synthesis/transport. Side effects: Pruritus, liver enzyme elevations; contraindications in advanced cirrhosis. MDPI

9. Odevixibat (BYLVAY) — Class: Ileal bile acid transporter (IBAT) inhibitor. Dose: 40 mcg/kg daily, up-titrate to 120 mcg/kg (per PFIC label). Purpose: Approved for PFIC pruritus; some BRIC2 patients share ABCB11 biology—use is off-label, specialist-guided. Mechanism: Blocks bile acid re-uptake in ileum, lowering systemic bile acids. Side effects: Diarrhea, fat-soluble vitamin issues. FDA Access Data+1

10. Maralixibat (LIVMARLI) — Class: IBAT inhibitor. Dose: As per PFIC/ALGS labels. Purpose/Mechanism: Same class as odevixibat; off-label in BRIC may be discussed with specialists. Side effects: Diarrhea, vitamin deficiencies; spacing with bile-acid binders required. FDA Access Data+1

11. Antihistamines (e.g., hydroxyzine at bedtime) — Class: H1 blockers. Dose: Low dose at night. Purpose: Help sleep; limited effect on cholestatic itch itself. Mechanism: Sedation reduces perception of itch. Side effects: Drowsiness, dry mouth. MDPI

12. Gabapentin (night-time adjunct) — Class: Neuromodulator. Dose: Low bedtime dose, titrate. Purpose: Reduce central itch perception and improve sleep. Mechanism: Damps neuronal excitability. Side effects: Dizziness, somnolence. (Supportive data in chronic pruritus; off-label.) MDPI

13. Ondansetron — Class: 5-HT3 antagonist. Dose: Intermittent dosing in refractory itch (specialist). Purpose: Rescue in select cases. Mechanism: Modulates serotonergic itch pathways. Side effects: QT prolongation risk. (Evidence limited.) MDPI

14. Doxepin (low-dose) — Class: Tricyclic/antihistaminic. Purpose/Mechanism: Sedation + H1/H2 blockade for nocturnal itch; specialist oversight. Side effects: Anticholinergic effects. (Limited evidence.) MDPI

15. Naloxone infusion (inpatient) — Class: Opioid antagonist. Purpose: Short-term severe itch rescue with monitoring. Mechanism: Reverses opioid-mediated itch signaling. Side effects: Withdrawal in opioid users; BP changes. MDPI

16. Rifapentine/rifaximin (investigational for itch) — Class: Rifamycin antibiotics. Purpose: Alternative enzyme induction/gut modulation; data limited vs rifampin. Mechanism: Similar induction or microbiome effects. Side effects: As class-related. MDPI

17. Cholestyramine light/powder formulations — Class: Sequestrant variants to improve adherence/palatability. Purpose/Mechanism: Same as #1. Side effects: Similar. FDA Access Data

18. Topical menthol/camphor gels — Class: Counter-irritants. Purpose: Local itch relief. Mechanism: TRPM8 cooling signals override itch. Side effects: Local irritation. AASLD

19. Short-course steroids (rare, specialist) — Class: Anti-inflammatory. Purpose: Selected cases with inflammatory triggers. Mechanism: Reduces intrahepatic inflammation; risks often outweigh benefits in BRIC. Side effects: Hyperglycemia, bone loss. PMC

20. Phenobarbital (legacy choleretic; rarely used) — Class: Enzyme inducer. Purpose/Mechanism: Increases bile flow/enzymes; replaced largely by safer options. Side effects: Sedation, dependence. MDPI

---

Dietary molecular supplements

1. Fat-soluble vitamins A, D, E, K (water-miscible forms as needed)
   Dose: Per measured deficiency (e.g., vitamin D 1000–2000 IU/day or protocol-based repletion). Function/Mechanism: Replace vitamins poorly absorbed during cholestasis, supporting vision (A), bones (D), nerves/antioxidant roles (E), and clotting (K). Note: Monitor levels; parenteral/water-miscible forms may be needed in significant cholestasis. PMC+1

2. Calcium
   Dose: 1000–1200 mg/day (diet±supplement). Function: Bone strength with vitamin D support. Mechanism: Counters bone demineralization during prolonged cholestasis. AASLD

3. MCT oil
   Dose: Start small (e.g., 1 tsp with meals), titrate; avoid overuse. Function: Readily absorbed energy source when fat absorption is poor. Mechanism: Absorbs without bile; caution about essential fatty acid dilution. UVA School of Medicine+1

4. Essential fatty acids (omega-6/omega-3 from food or supplement)
   Dose: Diet-based or supplements as advised. Function: Replace losses when using MCTs; support membranes and inflammation balance. Mechanism: Provide essential linoleic/alpha-linolenic acids. PMC

5. SAMe (S-adenosyl-L-methionine)
   Dose: Common oral regimens 400–1200 mg/day in studies. Function: Methyl donor supporting bile flow and hepatocyte function; mixed evidence on itch. Mechanism: May improve membrane fluidity and detox pathways; trial results are inconsistent. PubMed+1

6. Vitamin B complex (including folate, thiamine)
   Dose: Standard daily amounts. Function: Support energy and neuropathy prevention during poor intake. Mechanism: Replace dietary shortfalls. ESPN Clinical Nutrition

7. Zinc
   Dose: 10–25 mg elemental/day short-term if low. Function: Taste, appetite, wound healing; deficiencies common in chronic liver disease. Mechanism: Restores enzyme function. ESPN Clinical Nutrition

8. Magnesium
   Dose: 200–400 mg/day as tolerated. Function: Muscle/nerve support; helpful if diuretics used for complications in other cholestatic diseases. Mechanism: Replaces losses; supports energy metabolism. ESPN Clinical Nutrition

9. Probiotics (adjunct)
   Dose: Per product. Function: Gut comfort and stool quality during bile-acid binders. Mechanism: Microbiome modulation; evidence in BRIC is limited. PMC

10. Protein supplements (whey/plant)
    Dose: To reach daily protein goals when appetite is low. Function: Preserve lean mass. Mechanism: Counters catabolism during flares. ESPN Clinical Nutrition

---

Immunity-booster / Regenerative / Stem-cell–related” drugs

There are no proven “stem cell drugs” for BRIC. The items below explain realistic, evidence-based options related to bile-acid handling and liver support; all require specialist oversight.

1. Odevixibat (IBAT inhibitor) — Dose: 40–120 mcg/kg/day (PFIC label). Function/Mechanism: Lowers enterohepatic bile-acid recycling to reduce systemic bile acids; can reduce itch and bile acids in related genetic cholestasis. Note: Off-label for BRIC; monitor vitamins. FDA Access Data

2. Maralixibat (IBAT inhibitor) — Dose: Per label (ALGS/PFIC). Function/Mechanism: Same class effect; may be considered case-by-case. FDA Access Data

3. UDCA (ursodiol) — Dose: 13–15 mg/kg/day. Function: Cytoprotection and bile flow support; sometimes shortens cholestasis. Mechanism: Replaces toxic bile acids. FDA Access Data

4. Rifampin (enzyme inducer) — Dose: 150–300 mg bid (max 600 mg/day without specialist). Function: Potent anti-pruritic via enzyme/transporter induction (not immune boost). Mechanism: Lowers pruritogens. FDA Access Data

5. Naltrexone (opioid antagonist) — Dose: 25–50 mg/day. Function: Central anti-pruritic; supports quality of life. Mechanism: Blocks opioid-mediated itch signaling. FDA Access Data

6. Fenofibrate (PPAR-α agonist) — Dose: Per lipid label. Function: Adjunct cholestasis support in some conditions; may reduce itch biochemistry. Mechanism: Alters bile acid metabolism and transport. MDPI

---

Procedures/Surgeries

1. Endoscopic Nasobiliary Drainage (ENBD)
   Procedure/Why: A tube drains bile externally for a short period during a severe flare; done via ERCP. Why done: Rapid itch relief and bile-acid reduction when medical therapy fails. Evidence: Case series show long-lasting remission in BRIC. Wiley Online Library+1

2. Partial External Biliary Diversion (PEBD)
   Procedure/Why: Creates a small stoma to divert bile outside the body. Why done: For refractory, frequent attacks (more common in PFIC; selected BRIC cases). Outcome: Can improve pruritus and growth parameters in related conditions. PMC+1

3. Ileal exclusion / internal biliary diversion (specialist centers)
   Procedure/Why: Surgical alteration of bile circulation. Why done: Reduce bile-acid reabsorption to lessen systemic load. Use: Case-by-case in genetic cholestasis spectrum. Children Network

4. Temporary external biliary drainage (catheter)
   Procedure/Why: External drain during extreme attacks when ENBD is not feasible. Why done: Symptom control and biochemical relief. PMC

5. Liver transplantation (very rare in BRIC)
   Procedure/Why: Considered only for uncontrollable, life-threatening disease or severe quality-of-life impairment unresponsive to other therapy. Why done: Replaces failing liver; not typical because BRIC is classically non-progressive between attacks. PMC

---

Preventions

1. Have a step-plan for flares (meds + ENBD access). AASLD

2. Review new medicines with a clinician to avoid cholestatic drugs. PMC

3. Keep hydration and regular meals to support bile flow. ESPN Clinical Nutrition

4. Maintain vitamin A/D/E/K sufficiency and monitor yearly if bilirubin >2 mg/dL. PMC

5. Vaccinate against hepatitis A/B as indicated. PMC

6. Avoid alcohol during/around attacks. ESPN Clinical Nutrition

7. Use itch skin-care routines early in a flare. AASLD

8. Keep a symptom diary to catch patterns & triggers. AASLD

9. Regular specialist follow-up between episodes. Journal of Hepatology

10. Plan nutrition support if attacks last >2–3 weeks. ESPN Clinical Nutrition

---

When to see a doctor

1. See a doctor promptly if a flare begins (itch/jaundice), if stools turn pale or urine turns tea-colored, or if fatigue/anorexia worsen—these signs mean cholestasis is active.
2. Seek urgent care for fever, right-upper-quadrant pain, confusion, severe dehydration, bleeding, or rapidly deepening jaundice; these may signal infection, obstruction, or complications and need rapid tests (labs, ultrasound) and step-up therapy. PMC

---

What to eat and what to avoid

Do (examples):

1. Small, frequent meals for energy. 2) Lean proteins (fish, eggs, legumes). 3) Complex carbs (rice, oats). 4) Fruits/veg that you tolerate. 5) Consider MCT oil if advised. 6) Include sources of essential fatty acids (nuts, seeds, vegetable oils) if using MCTs. 7) Adequate calcium + vitamin D foods/supplements. 8) Stay well-hydrated. 9) Choose low-irritant, bland foods during nausea. 10) Use water-miscible ADEK vitamins if needed. ESPN Clinical Nutrition+1

Avoid/limit (examples):

1. Alcohol in/around attacks. 2) Very fatty, fried meals if they worsen symptoms. 3) Unnecessary herbal products with hepatotoxic risk. 4) Large single meals that aggravate nausea. 5) High-dose vitamin A/E without testing. 6) Prolonged fasting. 7) Energy drinks/excessive caffeine if sleep is poor. 8) Unsupervised weight-loss diets. 9) Overuse of MCT without essential fatty acid balance. 10) Grapefruit with certain meds (interaction check). ESPN Clinical Nutrition+1

---

Frequently Asked Questions

1. Is BRIC life-threatening?
   Usually no. Attacks are intense but often self-limited; between attacks people are well. Rarely, severe or frequent attacks need advanced treatments. Orpha

2. What genes are involved?
   Most often ATP8B1 (BRIC1) and ABCB11/BSEP (BRIC2); other rare genes are reported. PMC+1

3. How long do attacks last?
   Weeks to months; frequency varies widely between people. Tracking helps predict patterns. Orpha

4. Can BRIC progress to cirrhosis?
   Classically “benign,” but careful follow-up is advised; some genetic spectrums overlap with PFIC. PMC

5. What is first-line itch treatment?
   Cholestyramine; if inadequate, rifampin, naltrexone, then sertraline per guidance. AASLD+1

6. Do antihistamines help?
   They help sleep, not the core cholestatic itch mechanism. MDPI

7. What if medicines don’t work?
   Short-term ENBD or bile diversion procedures can be considered in severe, refractory flares. Wiley Online Library

8. Are there new drugs?
   IBAT inhibitors (odevixibat, maralixibat) are FDA-approved for PFIC/ALGS pruritus and may be discussed off-label for select BRIC—specialist decision. FDA Access Data+1

9. Is UDCA helpful?
   Sometimes; it improves bile chemistry in many cholestatic disorders, but itch relief varies. FDA Access Data

10. Do vitamins matter?
    Yes—monitor and replace vitamins A, D, E, K to protect eyes, bones, nerves, and clotting. PMC

11. Can stress worsen itch?
    Stress can amplify itch perception; relaxation and CBT techniques help coping. AASLD

12. Are herbal cleanses safe?
    Many herbs can be hepatotoxic; avoid unsupervised products. ESPN Clinical Nutrition

13. Will pregnancy affect BRIC?
    Cholestasis can worsen in pregnancy; close hepatology/obstetric monitoring is essential. (General cholestasis principle.) PMC

14. Is BRIC contagious?
    No, it is inherited, not infectious. MedlinePlus

15. Who should coordinate my care?
    A hepatologist with genetics input; have an agreed “flare plan” for rapid treatment. Journal of Hepatology

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 21, 2025.

PDF Documents For This Disease Condition References